



MOLECULAR DIAGNOSTIC TESTING REQUISITION

PATIENT INFORMATION (COMPLETE ONE FORM FOR EACH PERSON TESTED)

Patient Last Name	Patient First Name	MI	Date of Birth (MM / DD / YYYY)	
Address	City	State	Zip	Phone
Accession #	Hospital / Medical Record #	Genetic Sex: ☐ Female ☐ Male ☐ Unknown Gender identity (if different from above):		

Note: All reports will be sent via fax except for international recipients.

ORDERING PHYSICIAN

ADDITIONAL REPORTS

Ordering Physician	Institution Code	Name	Name
Institution Name		Email	Email
Email (Required for International Clients)		Phone	Phone
Phone	Fax	Fax	Fax

Note: Reports will be sent by FAX except for international recipients

PAYMENT (FILL OUT ONE OF THE OPTIONS BELOW)

☐ SELF PAYMENT

☐ INSTITUTIONAL BILLING

Institution Name	Institution Code	Institution Contact Name	Institution Phone	Institution Contact Email
------------------	------------------	--------------------------	-------------------	---------------------------

☐ INSURANCE

☐ Do Not Perform Test Until Patient is Aware of Out-Of-Pocket Costs (excludes prenatal testing)

REQUIRED ITEMS

1. Copy of the Front/Back of Insurance Card(s)	2. ICD10 Diagnosis Code(s)
3. Name of Ordering Physician	4. Insured Signature of Authorization

Primary Insurance Co. Name	Primary Insurance Co. Phone	Secondary Insurance Co. Name	Secondary Insurance Co. Phone
Primary Member Policy #	Primary Member Group #	Secondary Member Policy #	Secondary Member Group #
Name of Insured	Insured Date of Birth (MM / DD / YYYY)	Name of Insured	Insured Date of Birth (MM / DD / YYYY)
Patient's Relationship to Insured	Phone of Insured	Patient's Relationship to Insured	Phone of Insured
Address of Insured		Address of Insured	
City	State	City	State
	Zip		Zip

By signing below, I hereby authorize Baylor Genetics to provide my insurance carrier any information necessary, including test results, for processing my insurance claim. I understand that I am responsible for any co-pay, co-insurance, and unmet deductible that the insurance policy dictates. If self-pay is selected, I agree to pay for the cost of testing ordered and billed by Baylor Genetics as outlined in the Good Faith Estimate I received. I understand that I am responsible for sending Baylor Genetics any and all payments that I receive directly from my insurance company in payment for this test. Please note, Medicare may not cover certain screening tests.

Patient / Guardian Printed Name	Patient / Guardian Signature	Date (MM / DD / YYYY)
---------------------------------	------------------------------	-----------------------

STATEMENT OF MEDICAL NECESSITY AND CONSENT TO TERMS & CONDITIONS FOR TEST ORDER (REQUIRED)

This requisition hereby incorporates the Terms and Conditions of the Laboratory Services found at <https://www.baylorgenetics.com/lab-terms-conditions/> or, in the case of international entities, <https://www.baylorgenetics.com/terms-conditions-of-the-laboratory-services-international/>. This test is medically necessary for the risk assessment, diagnosis, or detection of a disease, illness, impairment, symptom, syndrome, or disorder. The results will determine my patient's medical management and treatment decisions. The person listed as the Ordering Physician is authorized by law to order the test(s) requested herein. I confirm that I have provided genetic testing information to the patient, and they have consented to genetic testing.

Physician's Printed Name	Physician's Signature	Date (MM / DD / YYYY)
--------------------------	-----------------------	-----------------------



MOLECULAR DIAGNOSTIC TESTING REQUISITION

Patient Last Name _____ Patient First Name _____ MI _____ Date of Birth (MM / DD / YYYY) _____ Genetic Sex _____

ETHNICITY

- ☐ African American ☐ Hispanic American ☐ Pacific Islander (Philippines, Micronesia, Malaysia, Indonesia)
☐ Ashkenazi Jewish ☐ Mennonite ☐ South Asian (India, Pakistan)
☐ East Asian (China, Japan, Korea) ☐ Middle Eastern (Saudi Arabia, Qatar, Iraq, Turkey) ☐ Southeast Asian (Vietnam, Cambodia, Thailand)
☐ Finnish ☐ Native American ☐ Southern European Caucasian (Spain, Italy, Greece)
☐ French Canadian ☐ Northern European Caucasian (Scandinavian, UK, Germany) ☐ Other (Specify): _____

SAMPLE

SAMPLE TYPE

- ☐ Blood in EDTA-tube (purple-top) ☐ DNA (Specify): _____ ☐ Skin Biopsy†
☐ Buccal Swab† ☐ Other (Specify): _____
☐ Cord Blood ☐ Saliva

DATE OF COLLECTION
(MM/DD/YYYY)

____ / ____ / ____

NOTE: Extracted DNA/RNA will only be accepted if the isolation of nucleic acids for clinical testing occurs in a CLIA-certified laboratory or a laboratory meeting equivalent requirements as determined by the CAP and/or the CMS.

Blood should not be sent from patients who have had a bone marrow transplant or recent blood transfusion
† Only accepted for FMR1 CGG Repeat Expansion Analysis (test code 6573)

INDICATION FOR TESTING (REQUIRED)

☐ Symptomatic (Summarize below)

☐ Symptomatic with Positive Family History

☐ Asymptomatic

☐ Population Screening

☐ Positive Family History

Disease _____ Gene _____ Variant _____

ICD10 Diagnosis Code(s)

TESTING OPTIONS

☐ Targeted Sequencing for Known Familial Mutation

(If selected, specify test code and gene below and complete section to the right)

Test Code _____ Gene _____

☐ Full Gene Sequencing

☐ Deletion/ Duplication Analysis

FOR TARGETED TESTING SELECTION ONLY

Proband Last Name _____ Proband First Name _____

Relationship to Proband _____ Date (MM / DD / YYYY) _____

PROBAND TESTING LOCATION (SELECT ONE)

☐ Baylor Genetics

☐ Another laboratory

Lab # _____ Family # _____

1. Attach a copy of the Proband test results
2. A positive control sample of the Proband is requested. Please provide, if available.

MOLECULAR DIAGNOSTIC TESTS

MASSIVELY PARALLEL SEQUENCING (BCM-MitomeNGSSM) PANELS

TEST CODE	TEST NAME	SAMPLE TYPE *
☐ 20100	Albinism Panel (13 genes)	BE, BUC, DNA
☐ 20400	Bardet-Biedl Syndrome Panel (18 genes)	BE, BUC, DNA
☐ 2105	Cholestasis Panel (7 genes)	BE, BUC, DNA
☐ 2100	CoQ10 Panel (PDSS1, PDSS2, COQ2, COQ9, and ADCK3)	BE, BUC, DNA
☐ 2120	Cobalamin Metabolism Panel + Severe MTHFR Deficiency (20 genes)	BE, BUC, DNA
☐ 2625	COL1A1/2-Related Disorders (COL1A1 & COL1A2)	BE, BUC, DNA
☐ 5095	Congenital Disorders of Glycosylation Panel (36 genes)	BE, BUC, DNA
☐ 2095	Fatty Acid Oxidation Deficiency Panel (20 genes)	BE, BUC, DNA
☐ 2125	Glycogen Storage Disease (GSD) Comprehensive Panel (23 genes)	BE, BUC, DNA
☐ 2126	Glycogen Storage Disease (GSD) Muscle Panel (13 genes)	BE, BUC, DNA
☐ 2127	Glycogen Storage Disease (GSD) Liver Panel (13 genes)	BE, BUC, DNA
☐ 2200	High Bone Mass Panel (14 genes)	BE, BUC, DNA
☐ 21700	Hyperinsulinism Panel (8 genes)	BE, BUC, DNA
☐ 21000	Hypoglycemia Panel (85 genes)	BE, BUC, DNA

* This sample type incurs an additional fee and typically adds 14 days to the turnaround time, depending on sample quality.

† Baylor Genetics will store this sample for up to 14 days after the report is issued, allowing for follow-up testing if needed.

MOLECULAR DIAGNOSTIC TESTING REQUISITION

Patient Last Name _____ Patient First Name _____ MI _____ Date of Birth (MM / DD / YYYY) _____ Genetic Sex _____

MOLECULAR DIAGNOSTIC TESTS

MASSIVELY PARALLEL SEQUENCING (BCM-MitomeNGSSM)

TEST CODE	TEST NAME	SAMPLE TYPE *	TEST CODE	TEST NAME	SAMPLE TYPE *
☐ 2090	Low Bone Mass Panel (23 genes)	BE, BUC, DNA	☐ 24001	Noonan Spectrum Disorders Panel (26 genes)	BE, BUC, DNA, SA
☐ 32870	Maple Syrup Urine Disease (MSUD) Panel (BCKHDA, BCKHDB, DBT, and DBD)	BE, BUC, DNA	☐ 22100	Peroxisomal Disorders Panel (22 genes)	BE, BUC, DNA
☐ 21900	Maturity-Onset Diabetes of the Young (MODY) Panel (25 genes)	BE, BUC, DNA	☐ 5274	Proximal Urea Cycle Disorders (PUCD Comprehensive (Seq. & Del/Dup) (CPS1, NAGS, OTC)	BE, BUC, DNA
☐ 2300	Myopathy/Rhabdomyolysis Panel (25 genes)	BE, BUC, DNA	☐ 2190	Retinitis Pigmentosa + RPGR orf15 by NGS (66 genes)	BE, BUC, DNA
☐ 20200	Nephronophthisis Panel (NPHP1, INVS/ NPHP2, NPHP3, and NPHP4)	BE, BUC, DNA	☐ 2110	Urea Cycle Disorders (UCD) and Hyperammonemia by NGS (8 genes)	BE, BUC, DNA

SINGLE GENE ANALYSIS

If a test is not found on this form, please obtain the test code from our website (www.BMGL.com) and write in the below space(s).

Test Code _____	Gene _____	Test Code _____	Gene _____	Test Code _____	Gene _____
Test Name _____		Test Name _____		Test Name _____	

TEST CODE	TEST NAME	DISORDER	SAMPLE TYPE *
☐ 5044	HSD17B10 Comprehensive (Seq & Del/Dup Analysis)	2-Methyl-3-Hydroxybutyryl-CoA Dehydrogenase Deficiency	BE, DNA
☐ 5064	HMGCL Comprehensive (Seq & Del/Dup Analysis)	3-Hydroxy-3-Methylglutaryl CoA Lyase Deficiency	BE, DNA
☐ 2874	MCCC1 and MCCC2 Comprehensive (Seq & Del/Dup Analysis)	3-Methylcrotonyl-CoA-Carboxylase Deficiency	BE, DNA
☐ 3639	MCCC1 Comprehensive (Seq & Del/Dup Analysis)	3-Methylcrotonyl-CoA-Carboxylase Deficiency	BE, DNA
☐ 3644	MCCC2 Comprehensive (Seq & Del/Dup Analysis)	3-Methylcrotonyl-CoA-Carboxylase Deficiency	BE, DNA
☐ 3914	AUH Comprehensive (Seq & Del/Dup Analysis)	3-Methylglutaconic Aciduria Type I	BE, DNA
☐ 6603	ABCA4 Comprehensive (Seq & Del/Dup Analysis)	ABCA4-Related Disorders	BE, DNA
☐ 3284	LPIN1 Comprehensive (Seq & Del/Dup Analysis)	Acute Recurrent Myoglobinuria (LPIN1-Related Disorders)	BE, DNA
☐ 2034	ACADSB Comprehensive (Seq & Del/Dup Analysis)	Acyl-CoA Dehydrogenase, Short/Branched Chain Deficiency	BE, DNA
☐ 2825	APRT Sequence Analysis	Adenine Phosphoribosyltransferase Deficiency	BE, DNA
☐ 5010	ADA Sequence Analysis	Adenosine Deaminase Deficiency	BE, DNA
☐ 3699	ADSL Comprehensive (Seq & Del/Dup Analysis)	Adenylosuccinase Deficiency	BE, DNA
☐ 5279	ABCD1 Comprehensive (Seq & Del/Dup Analysis)	Adrenoleukodystrophy	BE, DNA
☐ 3759	JAG1 Comprehensive (Seq & Del/Dup Analysis)	Alagille Syndrome	BE, DNA
☐ 2254	ALPL Comprehensive (Seq & Del/Dup Analysis)	ALPL-Related Disorders	BE, DNA
☐ 6490	AR Sequence Analysis	Androgen Insensitivity Syndrome	BE, DNA
☐ 6006	Angelman Syndrome (UBE3A) Methylation Analysis	Angelman Syndrome	BE, DNA
☐ 3429	ARG1 Comprehensive (Seq & Del/Dup Analysis)	Arginase Deficiency	BE, DNA
☐ 3459	GATM Comprehensive (Seq & Del/Dup Analysis)	Arginine: Glycine Amidinotransferase Deficiency	BE, DNA
☐ 6360	ASL Sequence Analysis	Argininosuccinate Lyase Deficiency	BE, DNA
☐ 6742	ARX Comprehensive (Seq & Del/Dup Analysis)	ARX-Related Disorders	BE, DNA

* Refer to Sample Specifications Table (page 11)

Panels continued on next page

MOLECULAR DIAGNOSTIC TESTING REQUISITION

Patient Last Name _____ Patient First Name _____ MI _____ Date of Birth (MM / DD / YYYY) _____ Genetic Sex _____

MOLECULAR DIAGNOSTIC TESTS
SINGLE GENE ANALYSIS

TEST CODE	TEST NAME	DISORDER	SAMPLE TYPE *
☐ 2205	AGA Sequence Analysis	Aspartylglycosaminuria	BE, DNA
☐ 6195	AIRE Sequence Analysis	Autoimmune Polyendocrinopathy 1	BE, DNA
☐ 3299	B4GALT7 Comprehensive (Seq & Del/Dup Analysis)	B4GALT7-Related Disorders	BE, DNA
☐ 3614	TAZ Comprehensive (Seq & Del/Dup Analysis)	Barth Syndrome (TAZ-Related Disorders)	BE, DNA
☐ 3499	BTD Comprehensive (Seq & Del/Dup Analysis)	Biotinidase Deficiency	BE, DNA
☐ 6012	Ashkenazic Mutation Panel (BLM)	Bloom Syndrome	BE, DNA
☐ 2429	LEMD3 Comprehensive (Seq & Del/Dup Analysis)	Buschke-Ollendorff Syndrome	BE, DNA
☐ 2589	TGFB1 Comprehensive (Seq & Del/Dup Analysis)	Camurati-Engelmann Disease	BE, DNA
☐ 6910	BRAF Sequence Analysis	Cardiofaciocutaneous Syndrome/ Costello Syndrome	BE, DNA
☐ 3439	SLC25A20 (CACT) Comprehensive (Seq & Del/Dup Analysis)	Carnitine Acylcarnitine Translocase Deficiency	BE, DNA
☐ 3364	SLC22A5 (OCTN2) Comprehensive (Seq & Del/Dup Analysis)	Carnitine Deficiency, Systemic	BE, DNA
☐ 3369	CPT1A Comprehensive (Seq & Del/Dup Analysis)	Carnitine Palmitoyltransferase IA Deficiency	BE, DNA
☐ 3374	CPT1B Comprehensive (Seq & Del/Dup Analysis)	Carnitine Palmitoyltransferase IB (CPT1B-Related Disorders)	BE, DNA
☐ 3164	CPT2 Comprehensive (Seq & Del/Dup Analysis)	Carnitine Palmitoyltransferase II Deficiency	BE, DNA
☐ 6125	RMRP Sequence Analysis	Cartilage Hair Hypoplasia (RMRP-Related Disorders)	BE, DNA
☐ 6733	CDKL5 Comprehensive (Seq & Del/Dup Analysis)	CDKL5-Related Disorders	BE, DNA
☐ 6376	CFTR Comprehensive Analysis (Seq, Del/Dup & 5T)	CFTR-Related Disorders (Cystic Fibrosis)	BE, DNA
☐ 6174	CHD7 Comprehensive (Seq & Del/Dup Analysis)	CHD7-Related Disorders (CHARGE Syndrome)	BE, DNA
☐ 6680	CHRNA7 Sequence Analysis	CHRNA7-Related Disorders	BE, DNA
☐ 3159	SLC25A13 (CTLN2) Comprehensive (Seq & Del/Dup Analysis)	Citrin Deficiency	BE, DNA
☐ 6180	ASS1 Sequence Analysis	Citrullinemia Type 1	BE, DNA
☐ 6150	RUNX2 Sequence Analysis	Cleidocranial Dysplasia	BE, DNA
☐ 3854	CABC1 (ADCK3) Comprehensive (Seq & Del/Dup Analysis)	Coenzyme Q10 Deficiency	BE, DNA
☐ 3419	COQ2 Comprehensive (Seq & Del/Dup Analysis)	Coenzyme Q10 Deficiency	BE, DNA
☐ 3414	PDSS2 Comprehensive (Seq & Del/Dup Analysis)	Coenzyme Q10 Deficiency	BE, DNA
☐ 7521	COL2A1 Comprehensive (Seq & Del/Dup Analysis)	COL2A1-Related Disorders	BE, DNA
☐ 6585	COL5A1 Sequence Analysis	COL5A1-Related Disorders	BE, DNA
☐ 6590	COL5A2 Sequence Analysis	COL5A2-Related Disorders	BE, DNA
☐ 3180	SDHA Sequence Analysis	Complex II Deficiency	BE, DNA
☐ 3185	SDHB Sequence Analysis	Complex II Deficiency	BE, DNA
☐ 3190	SDHC Sequence Analysis	Complex II Deficiency	BE, DNA
☐ 3195	SDHD Sequence Analysis	Complex II Deficiency	BE, DNA
☐ 2069	CYP17A1 Comprehensive (Seq & Del/Dup Analysis)	Congenital Adrenal Hyperplasia	BE, DNA
☐ 3259	CDG1A (PMM2) Comprehensive (Seq & Del/Dup Analysis)	Congenital Disorders of Glycosylation	BE, DNA
☐ 3454	CDG1B (MPI) Comprehensive (Seq & Del/Dup Analysis)	Congenital Disorders of Glycosylation	BE, DNA

* Refer to Sample Specifications Table (page 11)

Panels continued on next page

MOLECULAR DIAGNOSTIC TESTING REQUISITION

Patient Last Name _____ Patient First Name _____ MI _____ Date of Birth (MM / DD / YYYY) _____ Genetic Sex _____

MOLECULAR DIAGNOSTIC TESTS
SINGLE GENE ANALYSIS

TEST CODE	TEST NAME	DISORDER	SAMPLE TYPE *
☐ 5119	CDG1M (DOLK) Comprehensive (Seq & Del/Dup Analysis)	Congenital Disorders of Glycosylation	BE, DNA
☐ 6545	HRAS Sequence Analysis	Costello Syndrome	BE, DNA
☐ 3150	SLC6A8 (CT1) Sequence Analysis	Creatine Transporter (CRTR) Deficiency-Related Disorders	BE, DNA
☐ 6949	RPS19 Comprehensive (Seq & Del/Dup Analysis)	Diamond Blackfan Anemia-RPS19 Related Disorders	BE, DNA
☐ 5310	TBX1 Sequence Analysis	DiGeorge Syndrome	BE, DNA
☐ 3464	DLD Comprehensive (Seq & Del/Dup Analysis)	Dihydroliipoamide Dehydrogenase Deficiency	BE, DNA
☐ 6350	DMD Deletion/Duplication Analysis	DMD-Related Disorders	BE, DNA
☐ 2634	SLC39A13 Comprehensive (Seq & Del/Dup Analysis)	Ehlers-Danlos Syndrome, Spondylodysplastic Type 3	BE, DNA
☐ 6930	Type 4, STXBP1 Sequence Analysis	Epileptic Encephalopathy, Early Infantile	BE, DNA
☐ 7110	Type 7, KCNQ2 Sequence Analysis	Epileptic Encephalopathy, Early Infantile	BE, DNA
☐ 3749	ETHE1 Comprehensive (Seq & Del/Dup Analysis)	Ethylmalonic Encephalopathy	BE, DNA
☐ 6011	GLA Comprehensive (Seq & Del/Dup Analysis)	Fabry Disease	BE, DNA
☐ 2579	FAM20C Comprehensive (Seq & Del/Dup Analysis)	FAM20C-Related Disorders	BE, DNA
☐ 6740	LDLR Comprehensive (Seq & Del/Dup Analysis)	Familial Hypercholesterolemia	BE, DNA
☐ 6520	RUNX1 Sequence Analysis	Familial Platelet Disorder w/ Associated Myeloid Malignancy	BE, DNA
☐ 6573	FMR1 CGG Repeat Expansion	FMR1-Related Disorders (Fragile X Syndrome)	BE, BUC, DNA, SA
☐ 6570	FMR1 Sequence Analysis	FMR1-Related Disorders (Fragile X Syndrome)	BE, DNA
☐ 6345	PORCN Sequence Analysis	Focal Dermal Hypoplasia	BE, DNA
☐ 6690	FOXF1 Sequence Analysis	FOXF1-Related Disorders	BE, DNA
☐ 6031	Friedreich Ataxia Repeat Expansion Analysis	Friedreich Ataxia Syndrome	BE, DNA
☐ 6365	FXN Sequence Analysis	Friedreich Ataxia Syndrome	BE, DNA
☐ 3939	FBP1 Comprehensive (Seq & Del/Dup Analysis)	Fructose 1,6 Bisphosphatase Deficiency	BE, DNA
☐ 3740	FH Sequence Analysis	Fumarate Hydratase Deficiency (FH-Related Disorders)	BE, DNA
☐ 3279	GALE Comprehensive (Seq & Del/Dup Analysis)	Galactosemia	BE, DNA
☐ 3249	GALT Comprehensive (Seq & Del/Dup Analysis)	Galactosemia	BE, DNA
☐ 3799	GALK1 Comprehensive (Seq & Del/Dup Analysis)	Galactokinase Deficiency	BE, DNA
☐ 6955	SLC2A1 (GLUT1) Sequence Analysis	Glucose Transporter Type 1 Deficiency Syndrome	BE, DNA
☐ 3689	Type 1, GCDH Comprehensive (Seq & Del/Dup Analysis)	Glutaric Acidemia	BE, DNA
☐ 2044	Type 3, C7orf10 Comprehensive (Seq & Del/Dup Analysis)	Glutaric Acidemia	BE, DNA
☐ 5034	AMT Comprehensive (Seq & Del/Dup Analysis)	Glycine Encephalopathy	BE, DNA
☐ 3534	Type 0 Liver Isoform, GYS2 Comprehensive (Seq & Del/Dup Analysis)	Glycogen Storage Disease	BE, DNA
☐ 3839	Type 0 Muscle Isoform, GYS1 Comprehensive (Seq & Del/Dup Analysis)	Glycogen Storage Disease	BE, DNA
☐ 3134	Type 1a (GSD1A), G6PC Comprehensive (Seq & Del/Dup Analysis)	Glycogen Storage Disease	BE, DNA

* Refer to Sample Specifications Table (page 11)

Panels continued on next page

MOLECULAR DIAGNOSTIC TESTING REQUISITION

Patient Last Name

Patient First Name

MI

Date of Birth (MM / DD / YYYY)

Genetic Sex

MOLECULAR DIAGNOSTIC TESTS

SINGLE GENE ANALYSIS

TEST CODE	TEST NAME	DISORDER	SAMPLE TYPE *
☐ 3834	Type 1 (b,c,d), SLC37A4 (GSD1B) Comprehensive (Seq & Del/ Dup Analysis)	Glycogen Storage Disease	BE, DNA
☐ 3404	Type II, GAA Comprehensive (Seq & Del/Dup Analysis)	Glycogen Storage Disease	BE, DNA
☐ 3829	Type IV (GSDIV), GBE1 Comprehensive (Seq & Del/Dup Analysis)	Glycogen Storage Disease	BE, DNA
☐ 3804	Type V (GSDV), PYGM Comprehensive (Seq & Del/Dup Analysis)	Glycogen Storage Disease	BE, DNA
☐ 3794	Type VI (GSDVI), PYGL Comprehensive (Seq & Del/Dup Analysis)	Glycogen Storage Disease	BE, DNA
☐ 3824	Type VII (GSDVII), PFKM Comprehensive (Seq & Del/Dup Analysis)	Glycogen Storage Disease	BE, DNA
☐ 3984	Type IX (GSDIX), PHKG2 Comprehensive (Seq & Del/Dup Analysis)	Glycogen Storage Disease	BE, DNA
☐ 3809	Type X (GSDX), PGAM2 Comprehensive (Seq & Del/Dup Analysis)	Glycogen Storage Disease	BE, DNA
☐ 2529	Type XIII (GSDXIII), ENO3 Comprehensive (Seq & Del/Dup Analysis)	Glycogen Storage Disease	BE, DNA
☐ 2524	Type XIV (GSDXIV), PGM1 Comprehensive (Seq & Del/Dup Analysis)	Glycogen Storage Disease	BE, DNA
☐ 5129	GNE Comprehensive (Seq & Del/Dup Analysis)	GNE-Related Disorders	BE, DNA
☐ 3149	GAMT Comprehensive (Seq & Del/Dup Analysis)	Guanidinoacetate Methyltransferase Deficiency	BE, DNA
☐ 6019	Connexin 26 - GJB2 Sequence Analysis	Hearing Loss	BE, DNA
☐ 6355	Connexin 30 - GJB6 (232kb and 309kb) Deletion/Duplication Analysis	Hearing Loss	BE, DNA
☐ 3030	Mitochondrial Nonsyndromic Hearing Loss and Deafness Mutation Panel (MT-RNR1, MT-TS1, MT-TS2, MTRNR1)	Hearing Loss	BE, DNA
☐ 6395	MYO7A Sequence Analysis	Hearing Loss	BE, DNA
☐ 6655	CDH23 Sequence Analysis	Hearing Loss	BE, DNA
☐ 6670	POU3F4 Sequence Analysis	Hearing Loss	BE, DNA
☐ 3344	TIMM8A Comprehensive (Seq & Del/Dup Analysis)	Hearing Loss	BE, DNA
☐ 5405	Hemochromatosis Panel by Sanger Sequencing (HAMP, HFE, HFE2, SLC40A1, TFR2)	Hemochromatosis	BE, DNA
☐ 3129	ALDOB Comprehensive (Seq & Del/Dup Analysis)	Hereditary Fructose Intolerance	BE, DNA
☐ 3784	ALDOB, FBP1, GYS2, & PC Sequence Analysis	Hereditary Fructose Intolerance	BE, DNA
☐ 2145	SEPT9 Targeted Mutation Analysis	Hereditary Neuralgic Amyotrophy (HNA)	BE, DNA
☐ 6925	HEXA Sequence Analysis	Hexosaminidase A Deficiency/ Tay-Sachs Disease	BE, DNA
☐ 5390	HNRNPA1 Sequence Analysis	HNRNPA1-Related Disorders	BE, DNA
☐ 3544	HLCS Comprehensive (Seq & Del/Dup Analysis)	Holocarboxylase Synthetase Deficiency	BE, DNA
☐ 3974	CBS Comprehensive (Seq & Del/Dup Analysis)	Homocystinuria Caused by Cystathionine Beta-Synthase Deficiency	BE, DNA
☐ 2075	HPD Sequence Analysis	HPD-Related Disorders	BE, DNA
☐ 6034	Huntington Disease Repeat Expansion Analysis	Huntington Disease (Disease Specific Consent Required)	BE, DNA
☐ 5285	GLUD1 Sequence Analysis	Hyperinsulinism-Hyperammonemia Syndrome	BE, DNA
☐ 2070	GNMT Sequence Analysis	Hypermethioninemia	BE, DNA
☐ 2135	AHCY Sequence Analysis	Hypermethioninemia with S-Adenosylhomocysteine Hydrolase Deficiency	BE, DNA

* Refer to Sample Specifications Table (page 11)

Panels continued on next page

MOLECULAR DIAGNOSTIC TESTING REQUISITION

Patient Last Name

Patient First Name

MI

Date of Birth (MM / DD / YYYY)

Genetic Sex

MOLECULAR DIAGNOSTIC TESTS

SINGLE GENE ANALYSIS

TEST CODE	TEST NAME	DISORDER	SAMPLE TYPE *
☐ 3239	SLC25A15 (HHH) Comprehensive (Seq & Del/Dup Analysis)	Hyperornithinemia-Hyperammonemia-Homocitrullinuria (HHH) Syndrome	BE, DNA
☐ 5139	ALDH4A1 Comprehensive (Seq & Del/Dup Analysis)	Hyperprolinemia Type II	BE, DNA
☐ 2654	SLC34A1 (NPT2) Comprehensive (Seq & Del/Dup Analysis)	Hypophosphatemic Nephrolithiasis/Osteoporosis, 1	BE, DNA
☐ 5045	IYD Sequence Analysis	Hypothyroidism, Congenital	BE, DNA
☐ 5395	HNRNPA2B1 Sequence Analysis	Inclusion Body Myopathy with Early-Onset Paget Disease with or without Frontotemporal Dementia 2	BE, DNA
☐ 6036	Incontinentia Pigmenti Common Deletion Analysis	Incontinentia Pigmenti (IKBKG-Related Disorders)	BE, DNA
☐ 7100	IKBKG Sequence Analysis	Incontinentia Pigmenti (IKBKG-Related Disorders)	BE, DNA
☐ 3314	ABCB11 Comprehensive (Seq & Del/Dup Analysis)	Intrahepatic Cholestasis	BE, DNA
☐ 3319	ABCB4 Comprehensive (Seq & Del/Dup Analysis)	Intrahepatic Cholestasis	BE, DNA
☐ 3309	ATP8B1 Comprehensive (Seq & Del/Dup Analysis)	Intrahepatic Cholestasis	BE, DNA
☐ 2029	ACAD8 Comprehensive (Seq & Del/Dup Analysis)	Isobutyryl-CoA Dehydrogenase Deficiency	BE, DNA
☐ 3684	IVD Comprehensive (Seq & Del/Dup Analysis)	Isovaleric Acidemia	BE, DNA
☐ 6037	Kennedy Disease Repeat Expansion Analysis	Kennedy Disease	BE, DNA
☐ 5370	KIF11 Sequence Analysis	KIF11-Related Disorders	BE, DNA
☐ 6415	GALC Sequence Analysis	Krabbe Disease	BE, DNA
☐ 3389	ACADL Comprehensive (Seq & Del/Dup Analysis)	LCAD Deficiency	BE, DNA
☐ 3124	HADHA Comprehensive (Seq & Del/Dup Analysis)	LCHAD Deficiency (HADHA-Related Disorders)	BE, DNA
☐ 6065	PTPN11 Sequence Analysis	LEOPARD Syndrome	BE, DNA
☐ 6475	RAF1 Sequence Analysis	LEOPARD Syndrome	BE, DNA
☐ 6240	HPRT Sequence Analysis	Lesch-Nyhan Syndrome	BE, DNA
☐ 3719	DARS2 Comprehensive (Seq & Del/Dup Analysis)	Leukoencephalopathy	BE, DNA
☐ 3819	TRMU Comprehensive (Seq & Del/Dup Analysis)	Liver Failure, Acute Infantile	BE, DNA
☐ 6039	OCRL Sequence Analysis	Lowe Syndrome	BE, DNA
☐ 2039	ACSF3 Comprehensive (Seq & Del/Dup Analysis)	Malonic & Methylmalonic Aciduria, Combined	BE, DNA
☐ 2774	Type 1A, BCKDHA Comprehensive (Seq & Del/Dup Analysis)	Maple Syrup Urine Disease	BE, DNA
☐ 2884	Type 1B, BCKDHB Comprehensive (Seq & Del/Dup Analysis)	Maple Syrup Urine Disease	BE, DNA
☐ 3869	Type 2, DBT Comprehensive (Seq & Del/Dup Analysis)	Maple Syrup Urine Disease	BE, DNA
☐ 3119	ACADM Comprehensive (Seq & Del/Dup Analysis)	MCAD Deficiency	BE, DNA
☐ 6380	ARSA Sequence Analysis	Metachromatic Leukodystrophy (Arylsulfatase A Deficiency)	BE, DNA
☐ 2569	cbIE Type, MTRR Comprehensive (Seq & Del/Dup Analysis)	Methylcobalamin Deficiency	BE, DNA
☐ 2054	cbIG Type, MTR Comprehensive (Seq & Del/Dup Analysis)	Methylcobalamin Deficiency	BE, DNA
☐ 3602	Methylmalonic Acidemia Comprehensive Panel (MUT, MMAA, MMAB)	Methylmalonic Acidemia	BE, DNA
☐ 3399	MCEE Comprehensive (Seq & Del/Dup Analysis)	Methylmalonic Acidemia	BE, DNA
☐ 3579	MMAA Comprehensive (Seq & Del/Dup Analysis)	Methylmalonic Acidemia	BE, DNA

* Refer to Sample Specifications Table (page 11)

Panels continued on next page

MOLECULAR DIAGNOSTIC TESTING REQUISITION

Patient Last Name _____ Patient First Name _____ MI _____ Date of Birth (MM / DD / YYYY) _____ Genetic Sex _____

MOLECULAR DIAGNOSTIC TESTS
SINGLE GENE ANALYSIS

TEST CODE	TEST NAME	DISORDER	SAMPLE TYPE *
☐ 3584	MMAB Comprehensive (Seq & Del/Dup Analysis)	Methylmalonic Acidemia	BE, DNA
☐ 3444	MMACHC Comprehensive (Seq & Del/Dup Analysis)	Methylmalonic Acidemia	BE, DNA
☐ 3889	MMADHC Comprehensive (Seq & Del/Dup Analysis)	Methylmalonic Acidemia	BE, DNA
☐ 3589	MUT Comprehensive (Seq & Del/Dup Analysis)	Methylmalonic Acidemia	BE, DNA
☐ 2564	cbfI Type, LMBRD1 Comprehensive (Seq & Del/Dup Analysis)	Methylmalonic Aciduria and Homocystinuria	BE, DNA
☐ 3064	TYMP Comprehensive (Seq & Del/Dup Analysis)	MNGIE Syndrome	BE, DNA
☐ 3599	MOCS1 Comprehensive (Seq & Del/Dup Analysis)	Molybdenum Cofactor Deficiency	BE, DNA
☐ 3619	MOCS2 Comprehensive (Seq & Del/Dup Analysis)	Molybdenum Cofactor Deficiency	BE, DNA
☐ 6385	Type I (MPS I), IDUA Sequence Analysis	Mucopolysaccharidosis	BE
☐ 6814	Type II (MPS II), IDS Comprehensive (Seq & Del/Dup w/Inv Analysis)	Mucopolysaccharidosis	BE, DNA
☐ 3604	Multiple Acyl-CoA Dehydrogenase Deficiency (MADD) Comprehensive Panel (Seq & Del/Dup Analysis) (ETFA, ETFB, ETFDH)	Multiple Acyl-CoA Dehydrogenase Deficiency (MADD)	BE, DNA
☐ 3859	ETFA Comprehensive (Seq & Del/Dup Analysis)	Multiple Acyl-CoA Dehydrogenase Deficiency (MADD)	BE, DNA
☐ 3864	ETFB Comprehensive (Seq & Del/Dup Analysis)	Multiple Acyl-CoA Dehydrogenase Deficiency (MADD)	BE, DNA
☐ 3844	ETFDH Comprehensive (Seq & Del/Dup Analysis)	Multiple Acyl-CoA Dehydrogenase Deficiency (MADD)	BE, DNA
☐ 6041	Myotonic Dystrophy Type 1 Repeat Expansion Analysis	Myotonic Dystrophy Type 1	BE, DNA
☐ 3354	NAGS Comprehensive (Seq & Del/Dup Analysis)	N-Acetylglutamate Synthase (NAGS) Deficiency	BE, DNA
☐ 7523	LMX1B Comprehensive (Seq & Del/Dup Analysis)	Nail-Patella Syndrome	BE, DNA
☐ 6900	SHOC2 Sequence Analysis	Noonan-like Syndrome	BE, DNA
☐ 6845	LEP Sequence Analysis	Obesity, Monogenic Nonsyndromic	BE, DNA
☐ 6850	LEPR Sequence Analysis	Obesity, Monogenic Nonsyndromic	BE, DNA
☐ 6855	PCSK1 Sequence Analysis	Obesity, Monogenic Nonsyndromic	BE, DNA
☐ 6860	POMC Sequence Analysis	Obesity, Monogenic Nonsyndromic	BE, DNA
☐ 6083	X-Linked, GPR143 Comprehensive (Seq & Del/Dup Analysis)	Oculocutaneous Albinism	BE, DNA
☐ 3529	Type 3, OPA3 Comprehensive (Seq & Del/Dup Analysis)	Optic Atrophy Type 3	BE, DNA
☐ 3144	OTC Comprehensive (Seq & Del/Dup Analysis)	Ornithine Transcarbamylase (OTC) Deficiency	BE, DNA
☐ 2574	AMER1 Comprehensive (Seq & Del/Dup Analysis)	Osteopathia Striata with Cranial Sclerosis	BE, DNA
☐ 2624	TCIRG1 Comprehensive (Seq & Del/Dup Analysis)	Osteopetrosis	BE, DNA
☐ 2604	CA2 Comprehensive (Seq & Del/Dup Analysis)	Osteopetrosis with Renal Tubular Acidosis	BE, DNA
☐ 6885	PCDH19 Sequence Analysis	PCDH19-Related X Linked Female-Limited Epilepsy w/MR	BE, DNA
☐ 3169	PDHA1 Comprehensive (Seq & Del/Dup Analysis)	PDH Complex Deficiency	BE, DNA
☐ 3899	PDHB Comprehensive (Seq & Del/Dup Analysis)	PDH Complex Deficiency	BE, DNA
☐ 3924	PDHX Comprehensive (Seq & Del/Dup Analysis)	PDH Complex Deficiency	BE, DNA
☐ 3894	PDP1 Comprehensive (Seq & Del/Dup Analysis)	PDH Complex Deficiency	BE, DNA

* Refer to Sample Specifications Table (page 11)

Panels continued on next page

MOLECULAR DIAGNOSTIC TESTING REQUISITION

Patient Last Name _____ Patient First Name _____ MI _____ Date of Birth (MM / DD / YYYY) _____ Genetic Sex _____

MOLECULAR DIAGNOSTIC TESTS
SINGLE GENE ANALYSIS

TEST CODE	TEST NAME	DISORDER	SAMPLE TYPE *
☐ 6550	GJC2 Sequence Analysis	Pelizaeus-Merzbacher-Like Disease	BE, DNA
☐ 5365	PGM3 Sequence Analysis	PGM3-Related Disorders	BE, DNA
☐ 3139	PAH Comprehensive (Seq & Del/Dup Analysis)	Phenylalanine Hydroxylase Deficiency (PKU)	BE, DNA
☐ 6149	PLP1 Comprehensive (Seq & Del/Dup Analysis)	PLP1-Related Disorders	BE, DNA
☐ 3729	RARS2 Comprehensive (Seq & Del/Dup Analysis)	Pontocerebellar Hypoplasia Type 6	BE, DNA
☐ 6050	Prader-Willi Syndrome Methylation Analysis	Prader-Willi Syndrome	BE, DNA
☐ 7105	MAGEL2 Sequence Analysis	Prader-Willi-like Syndrome; Intellectual Disability; Autism	BE, DNA
☐ 3622	Propionic Acidemia Comprehensive Panel (Seq & Del/Dup Analysis) (PCCA & PCCB)	Propionic Acidemia	BE, DNA
☐ 6048	Prothrombin Mutation Panel (F2)	Prothrombin	BE, DNA
☐ 6790	PTEN Comprehensive (Seq & Del/Dup Analysis)	PTEN-Related Disorders	BE, DNA
☐ 5025	PNP Sequence Analysis	Purine Nucleoside Phosphorylase Deficiency	BE, DNA
☐ 2444	CTSK Comprehensive (Seq & Del/Dup Analysis)	Pycnodysostosis	BE, DNA
☐ 6950	ALDH7A1 Sequence Analysis	Pyridoxine-Dependent Seizures	BE, DNA
☐ 3919	DLAT Comprehensive (Seq & Del/Dup Analysis)	Pyruvate Dehydrogenase E2 Deficiency	BE, DNA
☐ 3754	PC Comprehensive (Seq & Del/Dup Analysis)	Pyruvate Carboxylase Deficiency	BE, DNA
☐ 5300	RAG2 Sequence Analysis	RAG2-Related Disorders	BE, DNA
☐ 6736	MECP2 Comprehensive (Seq & Del/Dup Analysis)	Rett Syndrome (MECP2-Related Disorders)	BE, DNA
☐ 6635	FOXP1 Sequence Analysis	Rett Syndrome, Congenital Variant	BE, DNA
☐ 6565	VDR Sequence Analysis	Rickets-Alopecia Syndrome	BE, DNA
☐ 6758	CREBBP Comprehensive (Seq & Del/Dup Analysis)	Rubinstein-Taybi Syndrome	BE, DNA
☐ 3929	ACADS Comprehensive (Seq & Del/Dup Analysis)	SCAD Deficiency	BE, DNA
☐ 6285	COL10A1 Sequence Analysis	Schmid Metaphyseal Chondrodysplasia (SMCD)	BE, DNA
☐ 6745	DHCR7 Sequence Analysis	Smith-Lemli-Opitz Syndrome	BE, DNA
☐ 6760	RAI1 Sequence Analysis	Smith-Magenis Syndrome	BE, DNA
☐ 6059	SMN1/SMN2 Copy Number Analysis	Spinal Muscular Atrophy (SMA) Diagnostic Test	BE, DNA
☐ 2899	PRKCG Comprehensive (Seq & Del/Dup Analysis)	Spinocerebellar Ataxia 14 (SCA14)	BE, DNA
☐ 6060	SRY Molecular Analysis	SRY-Related Phenotypes	BE, DNA
☐ 5024	ALDH5A1 Comprehensive (Seq & Del/Dup Analysis)	Succinic Semialdehyde Dehydrogenase Deficiency	BE, DNA
☐ 2510	TMLHE Sequence Analysis	TMLHE Deficiency	BE, DNA
☐ 2513	TMLHE Exon 2 Deletion Analysis	TMLHE Deficiency	BE, DNA
☐ 3969	TCN2 Comprehensive (Seq & Del/Dup Analysis)	Transcobalamin II Deficiency	BE, DNA
☐ 3624	Trifunctional Protein Deficiency Comprehensive Panel (Seq & Del/Dup Analysis) (HADHA and HADHB)	Trifunctional Protein Deficiency	BE, DNA

* Refer to Sample Specifications Table (page 11)

Panels continued on next page



MOLECULAR DIAGNOSTIC TESTING REQUISITION

Patient Last Name

Patient First Name

MI

Date of Birth (MM / DD / YYYY)

Genetic Sex

MOLECULAR DIAGNOSTIC TESTS

SINGLE GENE ANALYSIS

TEST CODE	TEST NAME	DISORDER	SAMPLE TYPE *
☐ 3634	HADHB Comprehensive (Seq & Del/Dup Analysis) (HADHB)	Trifunctional Protein Deficiency	BE, DNA
☐ 5005	TSHR Sequence Analysis	TSHR-Related Disorders	BE, DNA
☐ 3449	Type I, FAH Comprehensive (Seq & Del/Dup Analysis)	Tyrosinemia	BE, DNA
☐ 2084	Type II, TAT Comprehensive (Seq & Del/Dup Analysis)	Tyrosinemia	BE, DNA
☐ 6650	USH2A Sequence Analysis	Usher Syndrome 2A	BE, DNA
☐ 6660	CLRN1 Sequence Analysis	Usher Syndrome 3A	BE, DNA
☐ 3359	ACADVL Comprehensive (Seq & Del/Dup Analysis)	VLCAD Deficiency	BE, DNA
☐ 2554	ATP7B Comprehensive (Seq & Del/Dup Analysis)	Wilson Disease	BE, DNA
☐ 6430	LIPA Sequence Analysis	Wolman Disease	BE, DNA

SAMPLE SPECIFICATIONS TABLE

ABBREVIATION	SAMPLE NAME	RECOMMENDED AMOUNT		SHIPPING INSTRUCTIONS	SPECIAL NOTES
		(2 YRS - ADULT)	(NEWBORN - 2YRS)		
BE	Blood in EDTA tube (purple-top)	3 - 5 cc	2 - 3 cc	Ship at room temperature in an insulated container by overnight courier. Do not heat or freeze.	
BUC	Buccal Swab	See Special Notes	See Special Notes		Collected with ORAcollect•Dx (OCD-100) self-collection kit (provided by Baylor Genetics with instructions). It is highly recommended that the sample be collected by a healthcare professional. Buccal swab is an accepted sample type for FMR1 CGG Repeat Expansion Analysis (test code 6573) only.
CB	Cord Blood	N/A	1 - 2 cc		Ensure properly labeled. Also send 3 cc of maternal blood in properly labeled EDTA tube for MCC studies at no charge as needed.
DNA	DNA, Extracted	10 -15 ug	10 -15 ug		Minimal concentration of 50ng/uL; A260/A280 of ~1.7
SA	Saliva	See Special Notes	See Special Notes		Collected with Oragene DNA Self-Collection Kit.

INFORMED CONSENT FOR MOLECULAR DIAGNOSTIC TESTING

Patient Last Name

Patient First Name

MI

Date of Birth (MM / DD / YYYY)

Genetic Sex

GENERAL GENETIC TESTING CONSENT

This consent form cannot be used for whole exome sequencing (WES), whole genome sequencing (WGS), biochemical testing, or Huntington disease testing. Consent forms for other tests are located at Baylor Genetics' website (<https://www.baylorgenetics.com/consent/>).

For the purposes of this consent, "I", "my", "you", and "your" can refer to you, your child, your unborn child, or other individual you are the legal representative of.

TEST INFORMATION

Your healthcare provider (doctor, genetic counselor, or other person with medical training) wants to order one or more tests to find a cause for your health issues. This testing can see if there is a cause for your health issues or if there is an increased chance for a health issue to happen to you or your family. Some of these tests look for changes, called variants, in a person's DNA. DNA is our genetic material. You might have testing for variants in one or more genes, specific parts of DNA that are needed for our health. Variants can also be found in other places in the genome (all of the DNA that a person has). Some tests might look for changes in proteins or analytes that cause health issues. The testing ordered will depend on your health issues as well as what is already known about you and your family's genetics. These tests may also explain health issues that your family may have. Even if this test finds the cause of your health issues, this may not help treat or manage those issues.

Before you sign this consent form, you should speak with your healthcare provider. They can help you understand this testing and what it means for your health.

TEST RESULTS

There are several types of test results that may be reported including:

- **Positive:** A variant in the DNA was found that is related to your health issues or a health issue that you are at an increased risk of having in the future. These changes that cause disease are also known as pathogenic variants.
- **Negative:** No variants in the DNA were found that are related to your health issues or that would increase your risk of a health issue in the future.
- **Variant of Uncertain Clinical Significance (VUS):** A variant in the DNA was found that we do not know its effect, if any, on health. More testing may be needed for you or your family if a VUS is found that may be associated with your health issues.
- **Secondary and Incidental Findings:** Testing can sometimes find a variant in the DNA not related to the reason for testing. If this result is expected to affect your health, it is called a secondary or incidental finding.

CONSIDERATIONS AND LIMITATIONS

- You should speak with your provider before signing this consent form to understand the risks, benefits, and alternatives to testing.
- Testing may show you have, or are at increased chance of having, a health issue. It may show that you have an increased chance of having a child with a health issue.
- Even if the variant(s) causing your health issues are found, how these issues might progress or improve with treatment might not be known. Affected family members with the same variant might not be affected like you are.
- Depending on the results of testing, more testing may be needed to understand these results. This testing might be needed for you and/or other family members.
- A negative result does not rule out the chance for health issues. Our knowledge of variants and how they cause disease may change over time as we learn more about genetics. Testing has limitations to what it can find as well.
- Certain factors may lead to incorrect results. These include mislabeled samples, incorrect information in the test order, and rare technical errors.
- More sample may be needed from you if the first sample is not sufficient to complete testing.

PATIENT CONFIDENTIALITY AND SAMPLE RETENTION

- If several family members are tested, knowing the correct biological relationships among them is important. In rare cases, testing can show that family members are not related as expected. If this is found, we may contact the provider who ordered your testing.
- If this testing is requested to be cancelled after the order and sample are sent to the laboratory, please see our Test Cancellation Policy at www.baylorgenetics.com/cancel-test/.
- Only Baylor Genetics and its contracted partners will have access to your sample for the ordered testing. Results from testing will only be released to: (i) a licensed healthcare provider, (ii) those authorized in writing, (iii) the patient or their personal representative, and (iv) those allowed access to test results by law. You have the right to access your test results from Baylor Genetics by providing a written request. You also have the right to request raw data obtained from your sample by providing a written request or HIPAA Authorization Form.
- In rare cases, people with genetic diseases may have problems with health insurance and employment. The U.S. Federal Government has several laws that prohibit discrimination based on test results by health insurance companies and employers. These laws also prohibit unauthorized disclosure of this information. For more information, please visit www.genome.gov/10002077.
- Samples will be kept in the laboratory based on our retention policy. Once testing completes, de-identified sample may be used for test development, quality assurance, and training purposes. Samples are not returned to patients or providers unless requested prior to testing. You and your heirs will not receive payments, benefits, or rights to any resulting products or discoveries.
- The information from your testing may be used in scientific research, publications or presentations, but your specific identity will not be revealed. We may contact your provider to obtain more clinical information about you. Baylor Genetics also performs other types of scientific research and may contact you to see if you would like to be involved.
- Variants found may be submitted to databases. The medical community uses these databases to collect information about how variants might cause disease to improve testing and treatment for patients. An example is ClinVar, a free, public archive of reports on human genetics. Limited clinical information may need to be shared with these databases. In rare cases, this information may be enough to allow you or your family members to be identified.
- For more information on privacy practices at Baylor Genetics, please visit www.baylorgenetics.com/privacy-practices/.



INFORMED CONSENT FOR MOLECULAR DIAGNOSTIC TESTING

Patient Last Name Patient First Name MI ____ / ____ / ____
Date of Birth (MM / DD / YYYY) Genetic Sex

USE OF DATA AND SPECIMEN FOR RESEARCH PURPOSES

Biological specimens, test results, and associated information may be used by Baylor Genetics and its research partners for anonymous or coded research purposes, including improving genetic testing, advancing knowledge of genetic conditions, and developing new technologies, including inclusion in de-identified clinical databases, only with the patient's informed consent. Patient data and specimen will not be used for anonymous or coded research, unless authorized by marking below. A patient's decision to decline participation shall not affect their ability to receive testing from Baylor Genetics.

For Oregon patients, please consult the state specific consent form found at www.baylorgenetics.com/forms.

☐ I authorize Baylor Genetics the use of my specimen and de-identified data for research.

FOR SAMPLES FROM NEW YORK STATE RESIDENTS

Samples from New York State residents shall not be included in research without written consent. Samples will not be retained for more than sixty (60) days after receipt by Baylor Genetics, unless authorized by marking below. No tests other than those authorized shall be performed on the samples.

☐ I authorize Baylor Genetics to retain sample(s) longer based on our retention policy for test development, quality assurance, and training purposes.

FINANCIAL AGREEMENT

By signing below, I hereby authorize Baylor Genetics to provide my insurance carrier any information necessary, including test results, for processing my insurance claim. I understand that I am responsible for any co-pay, co-insurance, and unmet deductible that the insurance policy dictates. I designate Baylor Genetics as my designated representative for purposes of appealing any denial of benefits by my insurance carrier. I irrevocably assign associated payment to Baylor Genetics, and direct that payment be made directly to Baylor Genetics. Please note, some payers may not cover certain screening tests.

If my health insurer does not cover the test or I do not have health insurance, I have received a good faith estimate of the cost for the genetic testing ordered by my provider and agree to pay for the cost of the genetic testing billed to me by Baylor Genetics based on that good faith estimate. More information is available in Baylor Genetics' No Surprises Act and Good Faith Estimate Notice located at <https://www.baylorgenetics.com/no-surprises-act/>.

A Medicare Advance Beneficiary Notice (ABN) is required for services Medicare identifies as not medically necessary.

PATIENT AUTHORIZATION

By signing this statement of consent, I acknowledge that I have read, understand, and hereby grant my informed consent for genetic testing. I have received appropriate explanations from my healthcare provider about the planned genetic test(s) and possible results. I have been informed by my healthcare provider about the availability and importance of genetic counseling and have been provided with written information identifying a genetic counselor or medical geneticist who can provide such counseling services. All my questions have been answered, and I have had the necessary time to make an informed decision about the genetic test(s).

I hereby give permission to Baylor Genetics to conduct genetic testing as recommended by my physician*.

Patient Name Patient's Signature ____ / ____ / ____
Date Signed (MM / DD / YYYY)

Patient's Parent / Personal Representative* Name Patient's Parent / Personal Representative Signature ____ / ____ / ____
Date Signed (MM / DD / YYYY)

*If you are signing on behalf of the patient as the parent(s) and/or person with legal authority to act on behalf of the patient or parent, you may be required to provide evidence of your authority.